Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01558323 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of LCQ908 in Patients With Renal Impairment
A Phase 1 study of Renal Impairment, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 2
- Study locations
NCT01558323 is a Phase 1 study of Renal Impairment that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 58 participants, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (76% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT01558323, a Phase 1 study of Renal Impairment, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
Conditions Studied
Interventions
- DRUG LCQ908
Study Locations (2)
Florida
- Novartis Investigative Site - Orlando
Tennessee
- Novartis Investigative Site - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-05 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01558323
The ClinicalTrials.gov registry entry for NCT01558323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 33-participant average among 32 other Renal Impairment trials with a reported enrollment target (76% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Impairment appearing as the primary indexed condition, and to 1 intervention - of which LCQ908 is the first listed.
NCT01558323 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01558323 about?
NCT01558323 is a clinical study titled "Pharmacokinetics of LCQ908 in Patients With Renal Impairment". This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects
What is the current status of trial NCT01558323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2012-05. Estimated completion is 2013-03.
What conditions does trial NCT01558323 study?
This clinical trial studies the following conditions: Renal Impairment.
What interventions are being tested in trial NCT01558323?
The interventions under investigation include: LCQ908 (DRUG).
Who is sponsoring clinical trial NCT01558323?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01558323 being conducted?
This trial has 2 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
RECRUITING · Phase 1
-
A Study of S-892216-PO in Participants With Renal Impairment and Matched Controls
RECRUITING · Phase 1
-
Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373)
RECRUITING · Phase 1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Clinical Trial of MK-2828 in People With Kidney Disease (MK-2828-006)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.